Search

Your search keyword '"Busson, Pierre"' showing total 18 results
Start Over Author "Busson, Pierre" Publication Year Range Last 3 years
18 results on '"Busson, Pierre"'

1. Key enabling technologies for future wireless, wired, optical and satcom applications

Author

Debaillie, Björn, Ferrari, Philippe, Belot, Didier, Brunier, François, Gaquiere, Christophe, Busson, Pierre, and Steikūnienė, Urtė

Subjects
Telecommunications, Circuits, Devices, Communications engineering / telecommunications, Electronics: circuits and components, Electrical engineering
Abstract

This book presents the latest research roadmaps and achievements from the European ecosystem (industry, research, and academia) driving the development of future wireless, wired, optical and satcom applications utilising the mm-wave and sub-THz bands. It covers the entire value chain, including technologies, devices, characterisation, architectures, circuits, 3D heterogeneous integration and packaging. As the interconnectedness of our world continues to expand, the importance of global innovation in communication systems and technologies grows significantly. The increasing reliance on digital communication necessitates systems that can manage higher data traffic, provide faster and more reliable connectivity, and sustainably support a diverse range of applications. Achieving these goals requires a shift towards higher frequency bands (mm-wave and sub-THz) and the adoption of disruptive technologies. Heterogeneous integration of (Bi)CMOS, SOI, and III/V components such as GaN or InP, along with advanced packaging techniques, is essential to realise ubiquitous, ultra-high bandwidth, and low latency networks. To ensure that future communication systems are not only technologically advanced but also sustainable and responsible, it is crucial to minimize their environmental impact by considering the materials used, manufacturing processes, operational efficiency, and recyclability. The book captures the synergetic interactions between European Chips JU projects SHIFT and Move2THz, the European 3D heterogenous integration and packaging community and the MTT-TC9 society. These interactions were forged during the International Workshop on ""Key Enabling Technologies for Future Wireless, Wired, Optical and Satcom Applications"" at the European Microwave Week in Paris, France, on 22 September, 2024. Whether you are a professional in the field or simply interested in the future of communication technologies, this book offers invaluable insights into the technological breakthroughs shaping our digital future. The Open Access version of this book, available at http://www.taylorfrancis.com, has been made available under a Creative Commons Attribution-Non Commercial (CC-BY-NC) 4.0 license.

Published
2024
Full Text
View/download PDF

2. Correction: Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance

Author

Montégut, Léa, Liu, Peng, Zhao, Liwei, Pérez-Lanzón, María, Chen, Hui, Mao, Misha, Zhang, Shuai, Derosa, Lisa, Naour, Julie Le, Lambertucci, Flavia, Mingoia, Silvia, Nogueira-Recalde, Uxía, Mena-Osuna, Rafael, Herranz-Montoya, Irene, Djouder, Nabil, Baulande, Sylvain, Pan, Hui, Joseph, Adrien, Messaoudene, Meriem, Routy, Bertrand, Fidelle, Marine, Ben Ahmed, Tarek, Caron, Olivier, Busson, Pierre, Boulate, David, Deschasaux-Tanguy, Mélanie, Arnault, Nathalie, Pol, Jonathan G., Piaggio, Eliane, Touvier, Mathilde, Zitvogel, Laurence, Delaloge, Suzette, Martins, Isabelle, and Kroemer, Guido

Published
2024
Full Text
View/download PDF

3. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance

Author

Montégut, Léa, Liu, Peng, Zhao, Liwei, Pérez-Lanzón, María, Chen, Hui, Mao, Misha, Zhang, Shuai, Derosa, Lisa, Naour, Julie Le, Lambertucci, Flavia, Mingoia, Silvia, Nogueira-Recalde, Uxía, Mena-Osuna, Rafael, Herranz-Montoya, Irene, Djouder, Nabil, Baulande, Sylvain, Pan, Hui, Joseph, Adrien, Messaoudene, Meriem, Routy, Bertrand, Fidelle, Marine, Ben Ahmed, Tarek, Caron, Olivier, Busson, Pierre, Boulate, David, Deschasaux-Tanguy, Mélanie, Arnault, Nathalie, Pol, Jonathan G., Piaggio, Eliane, Touvier, Mathilde, Zitvogel, Laurence, Delaloge, Suzette, Martins, Isabelle, and Kroemer, Guido

Published
2024
Full Text
View/download PDF

6. Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts

Author

Nielsen, Morten A., Køster, Ditte, Mehta, Akul Y., Stengaard-Pedersen, Kristian, Busson, Pierre, Junker, Peter, Hørslev-Petersen, Kim, Hetland, Merete Lund, Østergaard, Mikkel, Hvid, Malene, Leffler, Hakon, Kragstrup, Tue W., Cummings, Richard D., Deleuran, Bent, Nielsen, Morten A., Køster, Ditte, Mehta, Akul Y., Stengaard-Pedersen, Kristian, Busson, Pierre, Junker, Peter, Hørslev-Petersen, Kim, Hetland, Merete Lund, Østergaard, Mikkel, Hvid, Malene, Leffler, Hakon, Kragstrup, Tue W., Cummings, Richard D., and Deleuran, Bent

Abstract

Background: Fibroblast-like synoviocytes (FLSs) are essential mediators in the expansive growth and invasiveness of rheumatoid synovitis, and patients with a fibroblastic-rich pauci-immune pathotype respond poorly to currently approved antirheumatic drugs. Galectin-9 (Gal-9) has been reported to directly modulate rheumatoid arthritis (RA) FLSs and to hold both pro- and anti-inflammatory properties. The objective of this study was to evaluate clinical and pathogenic aspects of Gal-9 in RA, combining national patient cohorts and cellular models. Methods: Soluble Gal-9 was measured in plasma from patients with newly diagnosed, treatment-naïve RA (n = 98). The disease activity score 28-joint count C-reactive protein (DAS28CRP) and total Sharp score were used to evaluate the disease course serially over a two-year period. Plasma and synovial fluid samples were examined for soluble Gal-9 in patients with established RA (n = 18). A protein array was established to identify Gal-9 binding partners in the extracellular matrix (ECM). Synovial fluid mononuclear cells (SFMCs), harvested from RA patients, were used to obtain synovial-fluid derived FLSs (SF-FLSs) (n = 7). FLSs from patients suffering from knee Osteoarthritis (OA) were collected from patients when undergoing joint replacement surgery (n = 5). Monocultures of SF-FLSs (n = 6) and autologous co-cultures of SF-FLSs and peripheral blood mononuclear cells (PBMCs) were cultured with and without a neutralizing anti-Gal-9 antibody (n = 7). The mono- and co-cultures were subsequently analyzed by flow cytometry, MTT assay, and ELISA. Results: Patients with early and established RA had persistently increased plasma levels of Gal-9 compared with healthy controls (HC). The plasma levels of Gal-9 were associated with disease activity and remained unaffected when adding a TNF-inhibitor to their standard treatment. Gal-9 levels were elevated in the synovial fluid of established RA patients with advanced disease, compared with corre, Background: Fibroblast-like synoviocytes (FLSs) are essential mediators in the expansive growth and invasiveness of rheumatoid synovitis, and patients with a fibroblastic-rich pauci-immune pathotype respond poorly to currently approved antirheumatic drugs. Galectin-9 (Gal-9) has been reported to directly modulate rheumatoid arthritis (RA) FLSs and to hold both pro- and anti-inflammatory properties. The objective of this study was to evaluate clinical and pathogenic aspects of Gal-9 in RA, combining national patient cohorts and cellular models. Methods: Soluble Gal-9 was measured in plasma from patients with newly diagnosed, treatment-naïve RA (n = 98). The disease activity score 28-joint count C-reactive protein (DAS28CRP) and total Sharp score were used to evaluate the disease course serially over a two-year period. Plasma and synovial fluid samples were examined for soluble Gal-9 in patients with established RA (n = 18). A protein array was established to identify Gal-9 binding partners in the extracellular matrix (ECM). Synovial fluid mononuclear cells (SFMCs), harvested from RA patients, were used to obtain synovial-fluid derived FLSs (SF-FLSs) (n = 7). FLSs from patients suffering from knee Osteoarthritis (OA) were collected from patients when undergoing joint replacement surgery (n = 5). Monocultures of SF-FLSs (n = 6) and autologous co-cultures of SF-FLSs and peripheral blood mononuclear cells (PBMCs) were cultured with and without a neutralizing anti-Gal-9 antibody (n = 7). The mono- and co-cultures were subsequently analyzed by flow cytometry, MTT assay, and ELISA. Results: Patients with early and established RA had persistently increased plasma levels of Gal-9 compared with healthy controls (HC). The plasma levels of Gal-9 were associated with disease activity and remained unaffected when adding a TNF-inhibitor to their standard treatment. Gal-9 levels were elevated in the synovial fluid of established RA patients with advanced disease, compared with co

Published
2023

7. Supplementary Data from Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSVΔ51) Combined with Radiation for Nasopharyngeal Carcinoma

Author

Alajez, Nehad M., primary, Mocanu, Joseph D., primary, Shi, Wei, primary, Chia, Marie C., primary, Breitbach, Caroline J., primary, Hui, Angela B.Y., primary, Knowles, Shane, primary, Bell, John C., primary, Busson, Pierre, primary, Takada, Kenzo, primary, Lo, Kwok-Wai, primary, O'Sullivan, Brian, primary, Gullane, Pat, primary, and Liu, Fei-Fei, primary

Published
2023
Full Text
View/download PDF

11. Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts

Author

Nielsen, Morten A., primary, Køster, Ditte, additional, Mehta, Akul Y., additional, Stengaard-Pedersen, Kristian, additional, Busson, Pierre, additional, Junker, Peter, additional, Hørslev-Petersen, Kim, additional, Hetland, Merete Lund, additional, Østergaard, Mikkel, additional, Hvid, Malene, additional, Leffler, Hakon, additional, Kragstrup, Tue W., additional, Cummings, Richard D., additional, and Deleuran, Bent, additional

Published
2023
Full Text
View/download PDF

13. Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

Author

Tran, Bao-Tram Thi, primary, Gelin, Aurore, additional, Durand, Sylvère, additional, Texier, Matthieu, additional, Daste, Amaury, additional, Toullec, Clémence, additional, Benihoud, Karim, additional, Breuskin, Ingrid, additional, Gorphe, Philippe, additional, Garic, Florence, additional, Brenner, Catherine, additional, Le Tourneau, Christophe, additional, Fayette, Jérôme, additional, Niki, Toshiro, additional, David, Muriel, additional, Busson, Pierre, additional, and Even, Caroline, additional

Published
2022
Full Text
View/download PDF

16. Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors.

Author

Tran, Bao-Tram Thi, Gelin, Aurore, Durand, Sylvère, Texier, Matthieu, Daste, Amaury, Toullec, Clémence, Benihoud, Karim, Breuskin, Ingrid, Gorphe, Philippe, Garic, Florence, Brenner, Catherine, Le Tourneau, Christophe, Fayette, Jérôme, Niki, Toshiro, David, Muriel, Busson, Pierre, and Even, Caroline

Subjects
HYPOPHARYNGEAL cancer, GALECTINS, HEAD & neck cancer, TRANSFORMING growth factors, CARCINOMA, HUMAN papillomavirus, SQUAMOUS cell carcinoma
Abstract

Extra-cellular galectins 1, 3 and 9 (gal-1, −3 and −9) are known to act as soluble immunosuppressive agents in various malignancies. Previous publications have suggested that their expression is dependent on the metabolic status of producing cells and reciprocally that they can influence metabolic pathways in their target cells. Very little is known about the status of gal-1, −3 and −9 in patients bearing head and neck squamous cell carcinomas (HNSCC) and about their relationships with the systemic metabolic condition. This study was conducted in plasma samples from a prospective cohort of 83 HNSCC patients with advanced disease. These samples were used to explore the distribution of gal-1, −3 and −9 and simultaneously to profile a series of 87 metabolites assessed by mass spectrometry. We identified galectin and metabolic patterns within five disease categories defined according to the primary site and human papillomavirus (HPV) status (HPV-positive and -negative oropharyngeal carcinomas, carcinomas of the oral cavity, hypopharynx and larynx carcinomas). Remarkably, samples related to hypopharyngeal carcinomas displayed the highest average concentration of gal-9 (p =.017) and a trend toward higher concentrations of kynurenine, a potential factor of tumor growth and immune suppression. In contrast, there was a tendency toward higher concentrations of fatty acids in samples related to oral cavity. These observations emphasize the diversity of HPV-negative HNSCCs. Depending on their primary site, they evolve into distinct types of immune and metabolic landscapes that seem to be congruent with specific oncogenic mechanisms. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma.

Author

Gessain G, Anzali AA, Lerousseau M, Mulder K, Bied M, Auperin A, Stockholm D, Signolle N, Sassi F, Marques Da Costa ME, Marchais A, Sayadi A, Weidner D, Uderhardt S, Blampey Q, Nakkireddy SR, Broutin S, Dutertre CA, Busson P, Walter T, Marhic A, Moya-Plana A, Guerlain J, Breuskin I, Casiraghi O, Gorphe P, Classe M, Scoazec JY, Blériot C, and Ginhoux F

Subjects
Humans, Prognosis, Giant Cells pathology, Giant Cells metabolism, Membrane Glycoproteins metabolism, Biomarkers, Tumor metabolism, Receptors, Immunologic metabolism, Receptors, Immunologic genetics, Macrophages metabolism, Squamous Cell Carcinoma of Head and Neck metabolism, Squamous Cell Carcinoma of Head and Neck pathology, Squamous Cell Carcinoma of Head and Neck genetics, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms pathology, Head and Neck Neoplasms diagnosis, Head and Neck Neoplasms genetics
Abstract

Significance: Novel individual biomarkers are needed to guide therapeutic decisions for patients with head and neck cancer. We report for the first time, granulomas of TREM2-expressing multinucleated giant macrophages in keratin-rich tumor niches, as a biomarker of favorable prognosis and developed a deep-learning model to automate its quantification on routinely stained pathological slides., (©2024 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

18. [Cancers of the upper aerodigestive tract: the particular case of nasopharyngeal cancer].

Author

Ferrand FR and Busson P

Subjects
Humans, Nasopharyngeal Carcinoma diagnosis, Nasopharyngeal Carcinoma therapy, Herpesvirus 4, Human, Nasopharyngeal Neoplasms diagnosis, Nasopharyngeal Neoplasms therapy, Nasopharyngeal Neoplasms pathology, Epstein-Barr Virus Infections complications, Epstein-Barr Virus Infections diagnosis, Epstein-Barr Virus Infections therapy, Head and Neck Neoplasms
Abstract

Nasopharyngeal carcinomas belong -in France- to the spectrum of rare diseases with several specificities owing to their etiology, epidemiology, diagnosis and therapeutics compared with other head and neck tumors. Educating physicians about the diagnostic and therapeutic elements of NPC and its functional consequences allows these patients to be better diagnosed and followed up during and after specific oncological treatment, and to enlighten them about the therapeutic options, in particular conformal radiotherapy, the mainstay of the management, and particularly effective systemic treatments. Prospects for treatment and follow-up are emerging, related or not to the specificity of this tumor often induced by the Epstein-Barr virus., Competing Interests: F.-R. Ferrand déclare participer à des interventions ponctuelles pour Merck, BMS, Pfizer. P. Busson déclare des interventions ponctuelles pour HiFiBiO Therapeutics.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results